700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Case Report Open Access
Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) represent the current standard for identification of therapeutically relevant anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers (NSCLCs). Use of tyrosine kinase inhibitors (TKIs) targeting the oncogenic ALK fusion protein is approved for use in advanced ALK-rearranged NSCLCs and with benefits both with regards to clinical outcomes and quality of life when compared with traditional palliative cytotoxic therapies. We report here 2 cases in which initial standard of care ALK testing by FISH yielded false positive results, leading to delays in determination of optimal systemic therapy.
Fluorescence, anaplastic lymphoma, Liver Cancer Case Reports, Bone cancer, Skin Cancer